来自食道癌细胞的小细胞外囊泡通过sEV-PDL1减少循环Tfh/Tfr,促进免疫抑制
Zijie Li1, Yuehua Zhang2, He Hao3
1Hebei Medical University, Shijiazhuang, 050011, Hebei, China.
Cancer immunology, immunotherapy : CII
|November 9, 2023
概括
在食道癌 (EC) 中,表达PD-L1 (sEV-PDL1) 的小细胞外囊泡破坏Tfh/Tfr细胞平衡,促进免疫逃生. 准sEV-PDL1可能会恢复这种平衡,并提供一种新的EC疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞外囊泡研究研究
背景情况:
- 食道癌 (EC) 的进展与免疫逃避有关.
- 表达编程死亡带1 (sEV-PDL1) 的小细胞外囊 (sEV) 有助于瘤免疫逃生.
- 循环毛囊辅助T细胞 (Tfh) 和毛囊调节T细胞 (Tfr) 之间的不平衡与各种癌症有关.
研究的目的:
- 研究EC衍生的sEV-PDL1在调节循环Tfh和Tfr细胞中的作用.
- 阐明sEV-PDL1影响Tfh/Tfr细胞平衡和功能的机制.
- 在欧洲共同体探索针对sEV-PDL1的治疗潜力.
主要方法:
- 流细胞测量检测循环Tfh和Tfr细胞在EC患者和健康捐赠者 (HDs).
- 从EC中分离和描述sEVs.
- 在体外共同培养试验中,使用具有sEVs的天真CD4+T细胞进行测定,以评估Tfh和Tfr细胞分化,表型和功能.
- 对细胞因子 (IL-21,IFN-γ,IL-10) 的分析.
- 对抗PDL1抗体治疗效果的评估.
主要成果:
- 与HD患者相比,EC患者的循环Tfh较低,循环Tfr较高,Tfh/Tfr比率较低.
- 在EC患者中观察到sEV-PDL1水平升高,与Tfh/Tfr比率负相关.
- 在体外,sEV-PDL1抑制了Tfh扩张,促进了Tfr扩张和免疫抑制功能,并改变了细胞因子的产生.
- 反PDL1抗体治疗逆转了sEV-PDL1.1的影响.
结论:
- 通过破坏循环中的Tfh/Tfr平衡,EC衍生的sEV-PDL1在免疫抑制中发挥着关键作用.
- sEV-PDL1促进Tfr细胞的扩张和功能,同时抑制Tfh细胞.
- 向sEV-PDL1代表了一种有前途的治疗策略,以恢复食道癌的免疫平衡.
更多相关视频
10:09Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
Published on: June 2, 2020
6.9K
12:02Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
Published on: November 11, 2021
4.2K
相关概念视频
Tumor Immunotherapy
533
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
533
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
